edoc

Nasal allergen neutralising IgG4 antibodies block IgE-mediated responses: novel biomarker of subcutaneous grass pollen immunotherapy

Shamij, Mohamed H. and Kappen , Jasper and Abubakar-Waziri, Hisham and Zhang, Jinjin and Watchman, Shelley and Steveling, Esther Helen and Watchman, Shelley and Kouser, Lubna and Eifan, Aarif and Switzer, Amy and Varrichi, Gilda and Marone, Gianni and Couto-Francisco, Natalia C. and Calderon, Moises and Durham, Stephen R.. (2018) Nasal allergen neutralising IgG4 antibodies block IgE-mediated responses: novel biomarker of subcutaneous grass pollen immunotherapy. Journal Of Allergy And Clinical Immunology, 143 (3). pp. 1067-1076.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/71728/

Downloads: Statistics Overview

Abstract

Background: Grass pollen subcutaneous immunotherapy (SCIT) is associated with induction of serum IgG 4 -associated inhibitory antibodies that prevent IgE-facilitated allergen binding to B cells. Objective: We sought to determine whether SCIT induces nasal allergen-specific IgG 4 antibodies with inhibitory activity that correlates closely with clinical response. Methods: In a cross-sectional controlled study, nasal fluid and sera were collected during the grass pollen season from 10 SCIT-treated patients, 13 untreated allergic patients (with seasonal allergic rhinitis [SAR]), and 12 nonatopic control subjects. Nasal and serum IgE and IgG 4 levels to Phleum pratense components were measured by using the Immuno Solid Allergen Chip microarray. Inhibitory activity was measured by IgE-facilitated allergen binding assay. IL-10 ⁺ regulatory B cells were quantified in peripheral blood by using flow cytometry. Results: Nasal and serum Phl p 1- and Phl p 5-specific IgE levels were increased in patients with SAR compared to nonatopic control subjects (all, P <.001) and SCIT-treated patients (nasal, P <.001; serum Phl p 5, P =.073). Nasal IgG 4 levels were increased in the SCIT group compared to those in the SAR group (P <.001) during the pollen season compared to out of season. IgG-associated inhibitory activity in nasal fluid and serum was significantly increased in the SCIT group compared to that in the SAR (both, P <.01). The magnitude of the inhibitory activity was 93% (P <.001) in nasal fluid compared to 66% (P <.001) in serum and was reversed after depletion of IgG. Both nasal fluid (r = −0.69, P =.0005) and serum (r = −0.552, P =.0095) blocking activity correlated with global symptom improvement. IL-10 ⁺ regulatory B cells were increased in season compared to out of season in the SCIT group (P <.01). Conclusion: For the first time, we show that nasal IgG 4 -associated inhibitory activity correlates closely with the clinical response to allergen immunotherapy in patients with allergic rhinitis with or without asthma.
Faculties and Departments:03 Faculty of Medicine > Bereich Spezialfächer (Klinik) > Dermatologie USB > Allergologie (Hartmann)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Spezialfächer (Klinik) > Dermatologie USB > Allergologie (Hartmann)
03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Allergy and Immunity (Hartmann)
UniBasel Contributors:Steveling-Klein, Esther Helen
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Mosby
ISSN:0091-6749
e-ISSN:1097-6825
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:08 Jul 2020 14:02
Deposited On:08 Jul 2020 14:02

Repository Staff Only: item control page